Peer-influenced content. Sources you trust. No registration required. This is HCN.

Features:
CME JOBS OUTBREAKS PEER-TO-PEER QUIZZES & QUESTIONS MEDTECH

Articles related to BIOSIMILARS

Specialty Pharmacy Continuum

Bright Future for Biosimilars

In 2023, patents for the two blockbusters Humira and Stelara will expire. The patents for Aranesp, Rituxan, Simponi, and others will expire in 2024, and in 2025, six more blockbuster drugs will experience patent expiration, opening the field to a rush of biosimilars. That could create an environment of significantly reduced drug prices.

All Specialties October 27th 2022

Tags: BIOSIMILARS DEVICE/DRUG APPROVALS HEALTHCARE COSTS

Topics

Sources

ACP Internist
Annals of Internal Medicine
ASH Clinical News
Blood
Blood Advances
British Medical Journal (The BMJ)
Cancer Therapy Advisor
Cleveland Clinic Journal of Medicine
Clinical Advances in Hematology & Oncology
GoodRx Health
Healthgrades for Professionals
JAMA Network
Journal of Clinical Oncology
MDLinx
MedPage Today
Medical Professionals Reference (MPR)
Neurology Advisor
Psychiatrist.com
ReachMD
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form